Novo Nordisk (CPSE:NOVO B) Stock Looks Cheap Even As Caution Lingers

Novo Nordisk stock has retreated over the past three years, yet the broader valuation checks still flag it as looking cheap rather than fully priced in. That mix of weak recent returns and a high value score gives investors a very different message to the cautious headlines around obesity drug competition and patent risk.

• The share price has declined about 53% over the past three years, which leaves Novo Nordisk trading well below where longer term holders bought in.
• Progress on GLP-1 treatments such as Wegovy, including higher dose and oral versions, can support confidence in future cash flows. At the same time, concerns about market share shifts, patent expiries and tighter peptide regulation may cap how much investors are willing to pay for that story.
• The broader checks lean cheap, with Novo Nordisk scoring a high 5 out of 6 on value, which suggests the current price screens as undervalued on standard multiples.

The issue now is whether that apparent discount reflects mispricing or simply the market baking in real execution and regulatory risks around Novo Nordisk.

Spot opportunities that echo Novo Nordisk’s combination of weak recent returns and strong value indicators by scanning our curated list of 250 high quality undervalued stocks.

Is Novo Nordisk Still Cheap on Earnings?

P/E fits Novo Nordisk well because earnings still drive how most investors frame the GLP 1 opportunity and the patent concerns around it.

The stock trades on a P/E of 11.1x, which is roughly half the Pharmaceuticals industry average of 22.3x and well below the peer group on 23.0x. On the model that adjusts for Novo Nordisk’s margins, size and risk profile, a fair P/E closer to 30.3x is implied, so the current ratio sits far under that tailored benchmark. Despite recent headlines about patent cliffs and obesity competition, the market is pricing Novo Nordisk on a multiple that appears closer to a low expectation scenario than the sector norm.

On this P/E framework, Novo Nordisk stock appears undervalued compared with both its industry and the indicated fair multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Novo Nordisk pick up where the P/E puzzle leaves off and spell out which earnings, margin and growth paths would need to play out for the current share price to look too low or too high. Each scenario links its number to a clear view on Novo Nordisk's future profitability and risk profile, which you can refer back to as fresh results, trial data or regulatory updates come through on the Community page.

Community views on Novo Nordisk could hardly be further apart, with one camp focused on a long runway and the other on practical limits to the story.

Bull case: 66% undervalued

"Novo Nordisk has built a formidable economic moat ("Burggraben") through decades of expertise in diabetes care, world-class manufacturing, and a trusted global brand..."

Read the full Bull Case to see why Novo Nordisk could be undervalued

Bear case: roughly fairly valued

"Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand..."

Read the full Bear Case to see why Novo Nordisk could be overvalued

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

Novo Nordisk screens as undervalued on market multiples, which points to expectation levels that look restrained compared with sector peers. That gap only matters if the business can keep converting the GLP 1 franchise into durable earnings while managing patent cycles and regulatory scrutiny. The key debate is whether the current discount reflects excessive caution or a fair response to very real execution risks, especially around capacity and competition. Your call comes down to one question: Does the market’s low bar for Novo Nordisk’s future profitability prove too harsh, or is it correctly flagging a possible value trap?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com